Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Kadonilimab plus salvage surgery for recurrent head and neck squamous cell carcinoma
ChiCTR2400079741Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in head and neck squamous cell carcinoma (HNSCC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Disease-free survival and Pathological remission rate. Started Jan 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2400079741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079741.